Application of a novel regulatable Cre recombinase system to define the role of liver and gut metabolism in drug oral bioavailability
The relative contribution of hepatic compared with intestinal oxidative metabolism is a crucial factor in drug oral bioavailability and therapeutic efficacy. Oxidative metabolism is mediated by the cytochrome P450 mono-oxygenase system to which cytochrome P450 reductase (POR) is the essential electr...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6949133/ https://www.ncbi.nlm.nih.gov/pubmed/25377919 http://dx.doi.org/10.1042/BJ20140582 |
_version_ | 1783485857779417088 |
---|---|
author | Henderson, Colin J. McLaughlin, Lesley A. Osuna-Cabello, Maria Taylor, Malcolm Gilbert, Ian McLaren, Aileen W. Wolf, C. Roland |
author_facet | Henderson, Colin J. McLaughlin, Lesley A. Osuna-Cabello, Maria Taylor, Malcolm Gilbert, Ian McLaren, Aileen W. Wolf, C. Roland |
author_sort | Henderson, Colin J. |
collection | PubMed |
description | The relative contribution of hepatic compared with intestinal oxidative metabolism is a crucial factor in drug oral bioavailability and therapeutic efficacy. Oxidative metabolism is mediated by the cytochrome P450 mono-oxygenase system to which cytochrome P450 reductase (POR) is the essential electron donor. In order to study the relative importance of these pathways in drug disposition, we have generated a novel mouse line where Cre recombinase is driven off the endogenous Cyp1a1 gene promoter; this line was then crossed on to a floxed POR mouse. A 40 mg/kg dose of the Cyp1a1 inducer 3-methylcholanthrene (3MC) eliminated POR expression in both liver and small intestine, whereas treatment at 4 mg/kg led to a more targeted deletion in the liver. Using this approach, we have studied the pharmacokinetics of three probe drugs – paroxetine, midazolam, nelfinavir – and show that intestinal metabolism is a determinant of oral bioavailability for the two latter compounds. The Endogenous Reductase Locus (ERL) mouse represents a significant advance on previous POR deletion models as it allows direct comparison of hepatic and intestinal effects on drug and xenobiotic clearance using lower doses of a single Cre inducing agent, and in addition minimizes any cytotoxic effects, which may compromise interpretation of the experimental data. |
format | Online Article Text |
id | pubmed-6949133 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
record_format | MEDLINE/PubMed |
spelling | pubmed-69491332020-01-08 Application of a novel regulatable Cre recombinase system to define the role of liver and gut metabolism in drug oral bioavailability Henderson, Colin J. McLaughlin, Lesley A. Osuna-Cabello, Maria Taylor, Malcolm Gilbert, Ian McLaren, Aileen W. Wolf, C. Roland Biochem J Article The relative contribution of hepatic compared with intestinal oxidative metabolism is a crucial factor in drug oral bioavailability and therapeutic efficacy. Oxidative metabolism is mediated by the cytochrome P450 mono-oxygenase system to which cytochrome P450 reductase (POR) is the essential electron donor. In order to study the relative importance of these pathways in drug disposition, we have generated a novel mouse line where Cre recombinase is driven off the endogenous Cyp1a1 gene promoter; this line was then crossed on to a floxed POR mouse. A 40 mg/kg dose of the Cyp1a1 inducer 3-methylcholanthrene (3MC) eliminated POR expression in both liver and small intestine, whereas treatment at 4 mg/kg led to a more targeted deletion in the liver. Using this approach, we have studied the pharmacokinetics of three probe drugs – paroxetine, midazolam, nelfinavir – and show that intestinal metabolism is a determinant of oral bioavailability for the two latter compounds. The Endogenous Reductase Locus (ERL) mouse represents a significant advance on previous POR deletion models as it allows direct comparison of hepatic and intestinal effects on drug and xenobiotic clearance using lower doses of a single Cre inducing agent, and in addition minimizes any cytotoxic effects, which may compromise interpretation of the experimental data. 2015-02-01 /pmc/articles/PMC6949133/ /pubmed/25377919 http://dx.doi.org/10.1042/BJ20140582 Text en http://creativecommons.org/licenses/by/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Licence (CC-BY) (http://creativecommons.org/licenses/by/3.0/) which permits unrestricted use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Article Henderson, Colin J. McLaughlin, Lesley A. Osuna-Cabello, Maria Taylor, Malcolm Gilbert, Ian McLaren, Aileen W. Wolf, C. Roland Application of a novel regulatable Cre recombinase system to define the role of liver and gut metabolism in drug oral bioavailability |
title | Application of a novel regulatable Cre recombinase system to define the role of liver and gut metabolism in drug oral bioavailability |
title_full | Application of a novel regulatable Cre recombinase system to define the role of liver and gut metabolism in drug oral bioavailability |
title_fullStr | Application of a novel regulatable Cre recombinase system to define the role of liver and gut metabolism in drug oral bioavailability |
title_full_unstemmed | Application of a novel regulatable Cre recombinase system to define the role of liver and gut metabolism in drug oral bioavailability |
title_short | Application of a novel regulatable Cre recombinase system to define the role of liver and gut metabolism in drug oral bioavailability |
title_sort | application of a novel regulatable cre recombinase system to define the role of liver and gut metabolism in drug oral bioavailability |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6949133/ https://www.ncbi.nlm.nih.gov/pubmed/25377919 http://dx.doi.org/10.1042/BJ20140582 |
work_keys_str_mv | AT hendersoncolinj applicationofanovelregulatablecrerecombinasesystemtodefinetheroleofliverandgutmetabolismindrugoralbioavailability AT mclaughlinlesleya applicationofanovelregulatablecrerecombinasesystemtodefinetheroleofliverandgutmetabolismindrugoralbioavailability AT osunacabellomaria applicationofanovelregulatablecrerecombinasesystemtodefinetheroleofliverandgutmetabolismindrugoralbioavailability AT taylormalcolm applicationofanovelregulatablecrerecombinasesystemtodefinetheroleofliverandgutmetabolismindrugoralbioavailability AT gilbertian applicationofanovelregulatablecrerecombinasesystemtodefinetheroleofliverandgutmetabolismindrugoralbioavailability AT mclarenaileenw applicationofanovelregulatablecrerecombinasesystemtodefinetheroleofliverandgutmetabolismindrugoralbioavailability AT wolfcroland applicationofanovelregulatablecrerecombinasesystemtodefinetheroleofliverandgutmetabolismindrugoralbioavailability |